BioSpace News Archive

Day Zero Diagnostics Doubles Down on epiXact ® Service for Investigating Healthcare-Associated Infection Outbreaks Supported by New NIH Funding Award SBIR Phase I Funds to Boost Speed of the Company’s Robust Sequencing and Analysis Service for Infection Control Professionals BOSTON--( BUSINESS WIRE )-- Day Zero Diagnostics, Inc. , an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious medical conditions, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the 13th Annual LD Micro Main Event virtual conference on December 14, 2020

The Company Exits Final Transitional Services Agreement and Announces the Consolidation of its North American Commercial Organizations

Patient enrollment completion anticipated by the end of April 2021 InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatment Therapy seeks to identify patient-specific foods that trigger IBS symptoms and suffering Approximately 45 million Americans suffer from IBS 1

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Irish subsidiary, has launched ILUVIEN® in the Netherlands.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with POINT Biopharma, Inc

Data presented at SABCS indicates benefits of oral paclitaxel and encequidar (oral paclitaxel) versus IV paclitaxel (IV P ) on Progression-Free Survival (PFS) and on Overall Survival (OS), which suppor ts superiority o n the primary endpoint Overall Response Rate (ORR) . In the intent - to - treat ( I TT) population, oral paclitaxel showed a benefit on PFS versus IVP , and showed a trend favoring oral paclitaxel on OS versus IVP.

Humacyte President and CEO Laura Niklason, M.D., Ph.D. will speak at the renowned Milken Institute Future of Health Summit on Wednesday, December 9 at 1:30 p.m. EST.